Breckenridge Pharmaceutical, Inc, a US-based subsidiary of Japan-based Towa Pharmaceutical, announced on Wednesday that it has introduced its Pencillamine Capsules, USP (generic for Cuprimine).
Aggrega Pharma, LLC has produced the product.
The company is to market the product on its own label and provide the 250mg strength in bottles of 100. It had earlier received the final approval of the Abbreviated New Drug Application (ANDA) for this product from the United States Food and Drug Administration (FDA).
Breckenridge Pharmaceutical signs new-product agreement with PTS Pharma
Dr. Reddy's Laboratories Launches Posaconazole Delayed-Release Tablets in the US Market
Nexus Pharmaceuticals unveils Erythromycin Lactobionate for Injection, USP in 500mg/vial
Breckenridge Pharmaceutical, Inc launches Pencillamine Capsules, USP
Breckenridge Pharmaceutical launches Lacosamide Tablets
Milla announces third ANDA approval & fourth US approval for the Alter Pharma Group